Hemostemix Stock Beta
| HEM Stock | CAD 0.07 0.01 7.14% |
Hemostemix fundamentals help investors to digest information that contributes to Hemostemix's financial success or failures. It also enables traders to predict the movement of Hemostemix Stock. The fundamental analysis module provides a way to measure Hemostemix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hemostemix stock.
Hemostemix | Beta |
Hemostemix Company Beta Analysis
Hemostemix's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Hemostemix Beta | 0.19 |
Most of Hemostemix's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemostemix is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hemostemix Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Hemostemix is extremely important. It helps to project a fair market value of Hemostemix Stock properly, considering its historical fundamentals such as Beta. Since Hemostemix's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hemostemix's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hemostemix's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Hemostemix has a Beta of 0.186. This is 78.37% lower than that of the Biotechnology sector and 86.62% lower than that of the Health Care industry. The beta for all Canada stocks is notably lower than that of the firm.
Hemostemix Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemostemix's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hemostemix could also be used in its relative valuation, which is a method of valuing Hemostemix by comparing valuation metrics of similar companies.Hemostemix is currently under evaluation in beta category among its peers.
As returns on the market increase, Hemostemix's returns are expected to increase less than the market. However, during the bear market, the loss of holding Hemostemix is expected to be smaller as well.
Hemostemix Fundamentals
| Return On Asset | -3.49 | ||||
| Current Valuation | 14.56 M | ||||
| Shares Outstanding | 140.64 M | ||||
| Shares Owned By Insiders | 9.54 % | ||||
| Number Of Shares Shorted | 11.93 K | ||||
| Price To Earning | (1.70) X | ||||
| Price To Book | 27.76 X | ||||
| EBITDA | (2.16 M) | ||||
| Net Income | (2.5 M) | ||||
| Cash And Equivalents | 49.36 K | ||||
| Total Debt | 4.32 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (1.5 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (0.03) X | ||||
| Target Price | 0.96 | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 10.55 M | ||||
| Total Asset | 313.76 K | ||||
| Retained Earnings | (63.27 M) | ||||
| Working Capital | (2.56 M) | ||||
| Net Asset | 313.76 K |
About Hemostemix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemostemix's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemostemix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemostemix based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.